Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 10;13:3236. doi: 10.1038/s41467-022-30979-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Schematic of experimental strategy. Specific RNA Pol1 blocker CX-5461 was used to ribogenesis, including RP translation. b Fibrillarin staining of hippocampal slices shows that nucleolar volume of CA1 pyr neurons is significantly reduced in both genotypes with 200 nM CX-5461 treatment by 45 min (WT: Veh = 100 ± 3.0%, CX 45’ = 85.9 ± 3.8%, CX 90’ = 90.8 ± 2.7%. One-way ANOVA *P = 0.0206, post hoc Veh-45’ *FDR = 0.0141, Veh-90’ FDR = 0.070. N = 20 neurons per group). (Fmr1^−/y: Veh = 100 ± 2.5%, CX 45’ = 90.96 ± 2.4%, CX 90’ = 90.05 ± 4.2%. One-way ANOVA *P = 0.0488, post hoc *Veh-45’ FDR = 0.0485, *Veh-90’ FDR = 0.0485, N = 20 neurons per group). c CA1-TRAP and qPCR analysis of Rps25 translation in hippocampal slices confirms an upregulation in the WT in response to DHPG at 30’ that is blocked with 200 nM CX-5461. DHPG does not elicit a significant increase in Rps25 translation in Fmr1^−/y slices nor does CX-5461 have a significant effect (WT: Veh = 100 ± 8.22%, DHPG = 127.9 ± 7.5%, CX + DHPG = 92.3 ± 9.5%. One-way ANOVA *P = 0.0388, post hoc Veh-DHPG *FDR = 0.0121, Veh-CXDHPG FDR = 0.3506, N = 7 littermate pairs. Fmr1^−/y: Veh = 100 ± 6.2%, DHPG = 119.6 ± 6.5%, CX + DHPG = 108.5 ± 10.9%. One-way ANOVA P = 0.2627). N = 7 littermate pairs. Data are presented as mean values + /− SEM. d, e mGluR-LTD was measured in hippocampal CA1 in the presence of vehicle or CX-5461. Slices were prepared from Fmr1^−/y and WT, recovered for at least 2 h, and exposed to vehicle or 200 nM CX-5461 for at least 30 min prior to DHPG application and throughout the LTD recording. CX-5461 causes a significant reduction in LTD magnitude in WT CA1 versus vehicle (Veh = 26.13% ± 3.5% N = 12 animals, CX-5461 = 13.00% ± 2.4% N = 10 animals, *FDR = 0.0031). In contrast, CX-5461 does not significantly reduce LTD magnitude in Fmr1^−/y CA1 versus vehicle (Veh = 36.337% ± 3.9% N = 11 animals, CX-5461 = 31.717% ± 2.3% N = 7, animals. FDR = 0.1224). f, g Quantification of all four groups show a differential effect of CX-5461 on LTD in each genotype (WT-Veh = 26.13% ± 3.5% N = 12 animals, WT-CX54611 = 13.00% ± 2.4% N = 10 animals, Fmr1^−/y Veh = 36.337% ± 3.9% N = 11 animals, Fmr1^−/y CX-5461 = 31.717% ± 2.3% N = 7, animals. Two-way ANOVA, genotype *P < 0.001 treatment *P = 0.01, post hoc: WT-Veh vs Fmr1^−/y-Veh *FDR = 0.0107, WT-Veh vs WT-CX-5461 *FDR = 0.0031, Fmr1^−/y-Veh vs Fmr1^−/y-CX-5461 FDR = 0.1224). Data are presented as mean values + /− SEM. Source data are provided as a Source Data file.